1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors
Condition: Pancreatic Cancer
Sponsor: Mirati Therapeutics, Inc.
Full Title
1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Study Treatment
Oral PRMT5 inhibitor MRTX1719
Eligibility/Info
Substudy 3: First or second line treatment of an MTAP deleted metastatic pancreatic adenocarcinoma. MRTX1719 in combination with nab-paclitaxel and gemcitabine.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: (631) 675-5075
HALO Messaging App: "Research Team"
Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.